Multiple genes have been shown to be independently hypermethylated in lymphoid malignancies. We report here on the extent of concurrent methylation of E-cadherin, O 6 MGMT, p73, p16, p15 and p14 in 129 pediatric ALL cases. While most of these genes demonstrated methylation in a proportion of cases, O 6 MGMT, p16 and p14 were infrequently methylated (11, 7 and 3%, respectively). Methylation of at least one gene was found in the vast majority (83%) of cases. To determine the extent and concordance of methylation we calculated a methylation index (MI ¼ number of methylated genes/number of studied genes) for each sample. The average MI was 0.28, corresponding to 2/7 methylated genes. MI was correlated with standard prognostic factors, including immunophenotype, age, sex, WBC and presence of specific translocations (TEL-AML1, BCR-ABL, E2A-PBX1 or MLL-AF4). We determined that children X10 years old and children presenting with high WBC (X50 Â 10 9 /l) both associated with a higher MI (Po0.01 and o0.05, respectively). T-ALLs demonstrated a lower MI (median ¼ 0.17) than precursor B ALLs (median ¼ 0.28). Among the different molecular subgroups, MLL-ALLs had the highest MI (mean ¼ 0.35), while ALLs carrying the t(1;19) had the lowest MI (mean ¼ 0.07). The most common epigenetic lesion in childhood ALL was methylation of E-cadherin (72%) independent of the molecular subtype or other clinicopathological factors.
Introduction
The major epigenetic modification of human genomic DNA is the methylation of cytosine residues located within the dinucleotide CpG. Hypermethylation occurs in a nonrandom, tissue-specific manner. It has been estimated that 3-4% of all cytosines are methylated in normal human DNA. 1 The distribution of CpG dinucleotides is not uniform throughout the genome; some regions are CpG-rich and thus denominated CpG islands. 2 These CpG islands are more common in the 5 0 region of genes (5 0 untranslated, promoter and exon 1). CpG islands are usually unmethylated in normal tissues, except in the case of imprinted genes, X chromosome in women, germline-or tissuespecific genes. [3] [4] [5] [6] Promoter hypermethylation causes a transcriptional block in the genes involved. Indeed, silencing of functionally relevant genes via aberrant DNA methylation has been linked to diverse human pathologies. 7, 8 Cancer has been recognized as a genetic disease for long time, but more recent data indicate that it can also be considered as an epigenetic disease. The normal epigenetic equilibrium is dramatically altered in tumor cells. Global hypomethylation of the genome occurs simultaneously with hypermethylation of CpG islands in critical genes such as tumorsuppressor genes. 9, 10 Genes silenced by this mechanism include genes that participate in every cellular process: cell cycle (Rb, p16, p15), DNA repair (BRCA1, MLH1, MGMT), apoptosis (DAP-kinase), drug-detoxification (GSTP1), etc. These changes are usually tumor-specific and therefore, not all the genes are methylated in all tumor types. Furthermore, some types of cancer demonstrate a characteristic 'methylator phenotype' in which multiple genes (mostly MINTs, methylated in tumors) are concurrently methylated. [11] [12] [13] It is not clear yet as to what causes these different patterns of methylation, but it is likely that some selective growth advantages are gained during transformation. It has been well documented that silencing of tumorsuppressor genes by promoter hypermethylation contributes to the transformation process. 14, 15 Several genes have been shown to be independently hypermethylated in hematological malignancies. [16] [17] [18] [19] [20] Recent studies have focused upon methylation analysis of multiple genes. Melki et al 21 first reported concurrent methylation of calcitonin, estrogen receptor (ER), E-cadherin, p15, p16 and Hic1, while Rb was unmethylated in AML. Toyota et al 22 studied other loci in AML and showed concurrent methylation of MyoD, Pitx2, Gpr37 and Scd4 from 12 loci analyzed in correlation with estrogen-receptor hypermethylation. Recent reports demonstrate significant methylation in adult ALL and stability in relapsed tumors. 23, 24 However, no specific methylator phenotype as described in solid tumors [11] [12] [13] has been reported in hematological malignancies. A correlation with prognosis has been suggested for individual genes such as p21 25 and O 6 MGMT. 26 Moreover, hypermethylation of p16 have been associated with disease progression inT-ALL, 27 while epigenetic modification of the ER has been associated with better outcome in AML. 28 Few reports that have studied childhood ALL mostly include single candidate genes [29] [30] [31] and only limited data are available on the extent of concurrent hypermethylation. 32 It is likely that the biology of childhood ALL is different from adult ALL and that different leukemogenic events control these disease entities. At least one study suggests that in spite of different and characteristic genetic lesions in adult and childhood ALL, epigenetic lesions may not be different in these diseases.
To determine clearly the methylation pattern in childhood ALL and to define if different subtypes show differences, we have studied a large series of samples at multiple loci. We determined the extent of concurrent hypermethylation of seven genes in 129 primary childhood ALLs and correlated these data with clinicopathological features.
Materials and methods

Clinical samples
Bone marrow aspirates (BM) or peripheral blood lymphocytes (PB) were obtained from 129 patients presenting with ALL at the time of diagnosis and prior to chemotherapy, following IRB approved projects and Institutional guidelines. The patients were o1-16 years of age, with a median age of 6 years ( Table 1 ). The inclusion of leukemic PB sample was restricted to those that contained more than 25% peripheral blasts. Mononuclear cells were isolated using Ficoll-Hypaque density gradient centrifugation and genomic DNA was extracted with the Purogene kit (Gentra, Minneapolis, MN, USA).
Sodium bisulfite modification of DNA
The procedure was previously described. Briefly, 5 mg of DNA was first denatured with 0.4 M NaOH for 30 min at 421C and then incubated in 3 M sodium bisulfite, 10 mM hydroquinone (Sigma, St Louis, MO, USA) at 551C for 16 h. Modified DNA was finally purified with Gene Clean III kit (Bio101, Vista, CA, USA), desulfonated with 0.4 M NaOH for 15 min at 371C and finally precipitated in ethanol and resuspended in dH 2 O.
Methylation-specific PCR (MSP)
A measure of 200 ng of sodium bisulfite modified DNA was used as template in PCR reactions containing 25 pmoles of each primer, 200 mM each dNTP, 1 U Hotstart Taq polymerase and 1 Â Q buffer (Qiagen, Valencia, CA, USA) in a final volume of 25 ml. Table 2 shows all the primers used, specific for the methylated (M) and the unmethylated (U) forms and the PCR conditions. These conditions were derived from (4) non-template (blank). PCR products were analyzed following electrophoresis on 4% agarose gels containing ethidium bromide. Specificity of each reaction was demonstrated when for each gene the M primers consistently yielded a band from IVM, the U primers produced a band from normal DNA and no bands were obtained from DNA not treated with bisulfite. Information on control monoclonal cell lines with completely methylated or completely unmethylated target genes was obtained from the literature and screened from the repository available in the Laboratory.
Cloning various PCR products and sequencing at least three clones from each further reconfirmed the M status of the p16 gene.
Real-time multiplex RT-PCR for determination of translocations
The presence of the four most frequent translocations, that is, 12;21, 1;19, 9;22 and 4;11, was determined whenever RNA was available by a real-time multiplex RT-PCR assay as previously described. 33 Other 11q23 rearrangements were determined by Southern blot analysis with an MLL probe.
Results
Each MSP was first standardized using bisulfite treated IVM as a positive control for methylation and bisulfite-treated normal DNA as a positive control for the absence of methylation. M primers consistently yielded a band when IVM was used as template. Similarly, U primers efficiently amplified the fragment of the correct length from normal DNA (Figure 1a) . None of the primers yielded any product in the absence of template or when non-bisulfite-treated DNA was used as template. The specificity of these reactions was further reconfirmed using cell lines with completely methylated or completely unmethylated loci that yielded the specific amplicon either with primers M or U but never with both. None of the cell lines used as controls for any given locus yielded cross-contamination or nonspecific PCR products ( Figure 1a) . The results were concordant with available published data.
In order to analyze if any background methylation in normal lymphocytes was likely to interfere with the assessment of leukemic samples under these conditions, we analyzed the methylation status of all the genes using DNA from healthy blood donors (12 adults and five children). All these normal samples demonstrated clear absence of methylation of DAPkinase, p73, O 6 MGMT, p16, p15 and p14 ( Figure 1a , lanes PBL 1-7). However, some background methylation of E-cadherin in normal controls was observed as previously reported. 34, 35 It is likely that these faint bands represent methylation in a small fraction of cells. Negative controls did not yield such bands. The intensity of these bands was visibly different than those observed in leukemic samples (in Figure 1 compare a with b) . Densitometric measurements indicated that the ratio between methylated and unmethylated bands was at an average 30-fold higher in patients than in normals.
We then analyzed 129 primary ALL samples obtained before treatment, including 99 of B-lineage and 30 of T-lineage. The clinical characteristics are shown in Table 1 . For most of the samples (105/129, 81%) DNA was sufficient for determination of the methylation status of all seven genes. However, for 16 cases (12%) we could analyzed six genes and for a minor number of samples (8/129, 6%) DNA was available for only five or four genes. The loci were chosen because they were previously described as aberrantly methylated in lymphoid malignancies. We used a methylation index (MI) to estimate and compare the extent of methylation in ALL (MI: ratio between the number of methylated genes and the number of analyzed genes). We compared bone marrow with peripheral blood (425% blasts) samples and no notable differences were elucidated (median MI-BM ¼ 0.26 and median MI-PB ¼ 0.28) based on the origin of the samples.
E-cadherin, DAP-Kinase, p73 and p15 showed methylation in a significant proportion of cases (72, 30, 26 and 23%). By contrast, O 6 MGMT, p16 and p14 were rarely altered (11, 7 and 3%, respectively). To detect methylation of p16 we used one of the strategies widely reported previously (MSP primers spanning 150 bp) and we confirmed our data by cloning and sequencing PCR products. This confirmed that all products corresponded to methylated p16; 75% of the clones carried all 11 CpG sites methylated and the remaining 25% of clones demonstrated lesser densities but at least four methylated sites. MI ranged from 0 to 1 with a median of 0.28, corresponding to two genes/sample. The majority of samples (83%) showed methylation of at least one gene and one-fifth demonstrated three or more methylated genes, indicated by an MI X0. 43 .
In order to analyze the coexistence of methylation in different loci in childhood ALL (Figure 2 ), we performed statistical analyses. For each gene, two-sided Fisher's exact tests were used to compare the frequency with which another locus was methylated when that gene was methylated or unmethylated. We only identified a statistical association between methylation in p16 and in DAP-kinase (Po0.005). Further coordination of methylation at the seven loci was analyzed by the Wilcoxon rank sum test comparing the status of each gene (M or U) with a MI calculated with the remaining genes. Again, DAP-kinase and p16 were the only genes that appeared more likely methylated in samples with greater extent of methylation (Po0.005 and o0.002, respectively). In contrast, methylation of p73, p15 and O 6 MGMT was equally distributed in all ranges of MI.
We then correlated methylation status with clinicopathological features at presentation, including age, sex, WBC and immunophenotype. Two associations were statistically significant. Leukemic samples from children X10 years old as well as leukemias from patients with WBC X50 Â 10 9 /l had higher MI (Po0.025 and o0.05, respectively). Moreover, a lesser extent of methylation was observed in T-ALLs (median MI ¼ 0.17) than in B-ALLs (median MI ¼ 0.28). Similarly, while 14% of B-ALLs did not demonstrate methylation of any gene, 27% of T-ALLs fell in this category. We also analyzed each locus with respect to these clinical parameters and observed that leukemias in children X10 years are more likely to inactivate p73 (Po0.005). Although the frequency of each gene methylation was generally similar in both immunophenotypic groups, for DAP-kinase it was clearly higher in B-ALLs (35%) than in T-ALLs (13%) (Po0.025).
To assess if the profile of methylation differed between molecular subgroups, we determined by real-time multiplex RT-PCR and Southern blot the presence of five common chromosomal rearrangements. t(12;21) was detected in 21/99 B-ALLs, t(1;19) in 4/99 cases, t(9;22) in 4/99 cases, 11q rearrangements in 7/99 patients and SIL-SCL rearrangement in 7/30 T-ALLs. Although the numbers of each subgroup are small, some interesting observations were noted. E2A-PBX1 leukemias showed the lowest MI (mean 0.07) and MLL leukemias had the highest MI (mean 0.35). T-ALLs with the SIL-SCL rearrangement demonstrated a lower MI (mean 0.10) than the T-ALLs without this rearrangement (mean 0.27). We then analyzed the frequency of methylation of each of the seven genes in these different molecular subtypes. A statistically significant difference was detected between the presence of methylated DAP-kinase in MLL-rearranged leukemias compared to the TEL-AML1 subtype (71 and 14%, respectively, Po0.05).
Discussion
There is growing evidence that DNA methylation plays a key role in silencing critical genes in cancer. 9, 10 We report in this study the pattern and degree of aberrant methylation of multiple genes in primary childhood ALL. We included samples from 99 patients with precursor B ALL and 30 patients with T-ALL. Seven candidate genes were chosen because they were epigenetically modified in lymphoid malignancies and associated with decreased expression in previous studies. These included E-cadherin, DAP-kinase, p73, p16, p15, p14 and O 6 MGMT. Hypermethylation of their 5 0 regions had been assayed by methylation-specific PCR (Table 2, Figure 1 ). It is likely that additional candidate genes are also relevant, including p21, p57, HIC, ER, etc and other novel loci. Further studies are needed to elucidate the complex epigenetic lesions.
The data presented here, nonetheless, demonstrate that multiple epigenetic lesions are frequent events in childhood Figure 2 Concurrent methylation of seven genes in childhood ALL. Precursor B ALLs that carry a known translocation (TEL-AML1, BCR-ABL, E2A-PBX1 or involving band 11q23) are shown in the first panel, precursor B ALLs that do not carry any of these rearrangements and a small proportion of cases that could not be analyzed are shown in the middle panel and T-ALLs are shown in the right panel. Green depicts methylation, yellow depicts unmethylation and blue depicts deletion of the gene. ALL (Figure 2) . In total, 83% of samples carried at least one methylated locus and one-fifth carried three or more altered loci. A study with a smaller cohort (N ¼ 16) and only three genes in common (p15, p16, p73), observed 93% of cases with some level of methylation and 13% with X3 modified promoters. 32 It is noteworthy that the frequencies of methylation do not differ notably between the studies. Both studies also indicate that p15 methylation is more common than p16 inactivation. In our larger series, this was even more notable in T-ALLs. There is still controversy on the role of these cyclin-dependent kinase inhibitors in lymphoid malignancies, 17, [36] [37] [38] suggesting that their inactivation may be critical only in a still undetermined molecular subtype of leukemia. For example, it has been reported that p16 methylation is frequent in MLL-leukemias, but we identified only one out of seven such cases. This is still different than none of the other 29 cases carrying translocations. Alternatively, geographic variations in methylation patterns may explain some differences. 39 O 6 MGMT was rarely methylated, distinguishing childhood ALL from other lymphoid malignancies such as diffuse large B-cell lymphomas. 26 Although it has been reported that 20% of adult ALLs do not express p14, 40 we did not find a significant level of methylation in pediatric cases. Two possibilities exist; either p14 inactivation is specific for adult ALL, or other mechanisms of inactivation participate in silencing p14 in childhood ALL. These examples support the hypothesis that aberrant CpG island hypermethylation is not only tissuespecific but also disease-specific and suggests an important role in pathogenetic mechanisms.
CpG island hypermethylation of the studied genes has been previously described as associated with gene silencing. We have also preliminary analyzed expression of DAP-kinase and E-cadherin by real-time quantitative RT-PCR and clearly observed that the presence of methylated CpG sites leads to a reduced level of transcripts (data not shown).
During statistical analyses of concomitant methylation in our cohort of patients, only p16 was significantly associated with DAP-kinase (Po0.05), suggesting that these two pathways, that is, allowing cell cycle to proceed and preventing apoptosis, may collaborate. Such a positive association was previously observed in tumors from head and neck. 41 Furthermore, these two loci were more likely to be methylated concurrently with other genes and therefore, they associated with a higher MI (Po0.005). Overall, methylation was not randomly distributed; however, discrete and unique methylator phenotypes as in solid tumors could not be established. Clearly, larger series are necessary to dissect these patterns that emerge from the data presented.
Comparison between precursor B-ALLs and T-ALLs demonstrated the existence of some differences in the pattern of methylation between lineages. Indeed, epigenetic modification of DAP-kinase was significantly lower in T-ALLs (13%) than in B-ALLs (35%) (Po0.025). A similar observation was reported in NHL from both lineages. 16 The extent of methylation also differed between lineages. T-ALLs were less methylated (median MI ¼ 0.17) than B-ALLs (median MI ¼ 0.28) and a higher fraction of T-ALLs had no methylation (27%) compared to B-ALLs (14%). These differences could reflect different etiologies and/or risk factors and may have relevant clinical implications because the extent of methylation will most likely determine the success of demethylating agents in future chemotherapeutic regimens.
Methylation of each locus and the MI for each sample were correlated to clinical data, specifically to standard prognostic factors from the patients at presentation. Some interesting observations arose. Age (X10 years) and WBC (X50 Â 10 9 /l) positively correlated with MI. It remains to be seen whether the extent of methylation can be used as an independent prognostic factor. Indeed, reports on single genes also suggested a prognostic value of aberrant epigenetic lesions. 25, 26, 28, 31 The association with WBC may indicate that promoter hypermethylation accumulates with increasing tumor burden and most likely with tumor progression. 27, 30 Wong et al 31 had previously shown that the frequencies of p15 and p16 methylation in ALL were higher in adults than in children. Our data suggest that the overall epigenetic modification is agedependent. Although Garcia-Manero et al 32 reported no differences between adult and pediatric ALL because no statistical significance was achieved, at least in p73, p15 and MDR1, there is a trend towards higher methylation in adults. In our larger cohort, methylation of p73 reached statistical significance. Lack of p73 expression has been found in a proportion of ALLs. 19 Although no inactivating mutations were found, hypermethylation of the promoter was associated with reduced disease-free survival. 42 Indeed, different etiologies between childhood and adult ALL may explain differences observed in methylation of certain genes like E-cadherin. For example, we found a higher frequency of methylated E-cadherin than previously reported for ALL -53% -that included adults. 18 Although this difference may be due to geographic variations, it can also be due to different age populations.
A direct clinical application of studies of methylation in tumor cells is the use of aberrant DNA methylation at certain sites as a biomarker of malignant transformation. [43] [44] [45] Indeed, some promoter hypermethylation can occur early in tumor progression. Furthermore, the positive PCR signal from such a lesion will not be masked by the presence of normal cells. These advantages could facilitate both early detection and assessment of minimal residual disease. We found that 72% of childhood ALL carry methylation of E-cadherin indicating that this is an early epigenetic event during leukemogenesis. Since an extremely low level of methylated E-cadherin promoter was detected in blood cells from healthy individuals, appropriate quantitative assays need to be first established. The presence of methylated E-cadherin across subtypes of ALL strongly suggests that this could be a convenient biomarker for early detection, for example of CNS involvement, and in follow-up studies.
